Fasciitis complicating subcutaneous injection of interferon beta

Canadian Journal of Gastroenterology

Volumn 14, Issue SUPPL. B, 2000, Pages

  Cooper, Curtis L ^a,b   Gerstein, Rachel ^a   Kaita, Kelly ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b Division of Infectious Diseases   (Canada)

Author keywords

Fasciitis; Hepatitis C virus; Interferon

Indexed keywords

BETA INTERFERON;

ADULT; ARTICLE; CASE REPORT; FASCIITIS; HEPATITIS C; HUMAN; MALE; RISK FACTOR; STAPHYLOCOCCUS INFECTION; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; FASCIITIS; HEPATITIS C; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON-BETA; MALE; RISK FACTORS; STAPHYLOCOCCAL INFECTIONS;

EID: 0034222629     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2000/969163     Document Type: Article

References (5)

1. McHutchinson JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-92.
2. Poynard T, Marcellin P, Lee SS, et al. Randomized trial of interferon alfa-2b plus ribivirin for 48 weeks or for 24 weeks versus interferon alfa-2b plus placebo for 48 for 48 weeks for treatment of chronic hepatitis C virus. Lancet 1998;352:1426-32.
3. Takano S, Satomura Y, Omata M. Effects of interferon beta on non-A, non-B acute hepatitis: a prospective, randomized, controlled-dose study. Japan Acute Hepatitis Cooperative Study Group. Gastroenterology 1994;107:805-11.
4. Perez R, Pravia R, Artimez ML, et al. Clinical efficacy of intramuscular human interferon-beta vs interferon-alpha 2b for the treatment of chronic hepatitis. J Viral Hepatol 1995;2:103-6.
5. Castro A, Carballo E, Dominquez A, et al. Tolerance and efficacy of subcutaneous interferon-beta administration for treatment of chronic hepatitis C. J Interferon Cytokine Res 1997;17:65-7.